Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
18F-labeled prostate-specific membrane antigen (PSMA) ligand-positron emission tomography
(PET) offers advantages over 68Ga-labeled PSMA ligands. Al18F-PSMA-617 is a novel 18F-PSMA
compound used for prostate cancer (PCa) imaging. This pilot study was prospectively designed
to compare the lesion detectability of Al18F-PSMA-617 and related 68Ga-PSMA-617 PET/CT in
patients with PCa